Evaluating risks of myelodysplastic syndrome in patients receiving peptide radionuclide therapy
Official title: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Run by University Health Network, Toronto · NCT06510868 · Data updated 2026-11-12
This study is trying to find out if certain patients who receive a specific cancer treatment are at risk of developing blood disorders like myelodysplastic syndrome and leukemia, to make the treatment safer for everyone.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | April 1, 2028 |
| Study ends | June 30, 2029 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT06510868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with neuroendocrine tumors who are either planning to undergo PRRT or have recently completed it.
✕Probably not a fit
Patients who are unwilling to provide blood samples or those with a life expectancy of less than six months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify patients at risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) following peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors. By analyzing genetic changes and patient responses, the study seeks to improve patient selection for PRRT and develop strategies to mitigate the risk of these serious conditions. The research will also explore whether the development of MDS and AML is linked to specific radioisotopes or is a broader effect of radiopharmaceuticals. Ultimately, the findings could enhance the safety and efficacy of PRRT in treating cancer.
Why it matters
Potential benefit: If successful, this study could lead to better patient selection for PRRT and strategies to prevent the development of MDS and AML.
How similar studies have gone: While the study explores a critical area of research, the specific approach of identifying genetic predispositions in the context of PRRT is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* ECOG 0-3
* Life expectancy \> 6 months
* Informed consent and willingness to undergoing serial genetic panel CHIP testing.
* Cohort Specific criteria
1. Cohort A: PRRT completed within 5 years of enrolment
2. Cohort B: PRRT planned to commence within 4 months of enrolment
3. Cohort C: diagnosis of MDS or AML following prior PRRT.
Exclusion Criteria:
* Unwillingness to provide blood sample and follow up as per protocol
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Rebecca Wong
- Email: rebecca.wong@uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Adding FHD-286 to low‑dose decitabine and venetoclax for adverse‑risk AML
This trial tests whether adding FHD-286 to a low‑dose decitabine plus venetoclax regimen helps people with newly diagnosed adverse‑risk acute myeloid leukemia or AML that progressed after one prior therapy.
-
Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant
This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.
-
Induction and consolidation using fludarabine, cytarabine, idarubicin, and venetoclax for acute myeloid leukemia
This trial tests whether adding venetoclax to induction and consolidation chemotherapy (fludarabine, cytarabine, and idarubicin) helps adults 18–65 with newly diagnosed acute myeloid leukemia or high-blast myelodysplastic syndrome achieve deeper remissions than standard cytarabine/daunorubicin therapy.
-
RPT1G for adults with relapsed or refractory acute myeloid leukemia and high-risk MDS
This study will test whether the drug RPT1G is safe and find the best dose for adults whose AML or high-risk MDS has come back or not responded to treatment.
-
FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers
This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.